Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Angiotensin-(1-7) vs GHK-Cu (Oral)
An educational, source-based comparison of Angiotensin-(1-7) and GHK-Cu (Oral) — how each peptide works, what it's researched for, and what to know before going deeper.
Counter-regulatory peptide of the renin-angiotensin system.
A heptapeptide of the renin-angiotensin system that acts on Mas receptors. Research demonstrates counter-regulatory effects to angiotensin II, promoting vasodilation, anti-inflammatory signaling, and anti-fibrotic effects in cardiovascular and renal tissues.
- Pulmonary hypertension and fibrosis
- Heart failure with preserved ejection fraction
- Acute lung injury and ARDS
- Diabetic nephropathy
- • Investigational; not FDA-approved.
- • Interaction with ACE inhibitors and ARBs requires careful study design.
An oral formulation of the GHK-Cu tripeptide designed for systemic absorption. Research suggests the same copper-complex gene-modulating activity as topical forms, potentially supporting systemic tissue repair, immune modulation, and antioxidant capacity.
- Systemic tissue repair and regeneration
- Immune modulation and inflammation
- Lung and gut tissue health
- Age-related gene expression restoration
- • Oral bioavailability is lower than injectable; optimal dosing unclear.
- • Not FDA-approved for therapeutic use.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Angiotensin-(1-7) | Angiotensin-(1-7) as a therapeutic in lung disease | American Journal of Respiratory and Critical Care Medicine | 2020 | Demonstrated protective effects in acute lung injury and pulmonary fibrosis models. |
| Angiotensin-(1-7) | Mas receptor activation in cardiovascular protection | Circulation Research | 2018 | Reviewed anti-inflammatory and anti-fibrotic mechanisms in cardiac tissue. |
| GHK-Cu (Oral) | Oral GHK-Cu absorption and systemic effects | BioMed Research International | 2021 | Detected in plasma after oral administration with modulated inflammatory biomarkers. |
Side-effect & safety grid
- Investigational; not FDA-approved.
- Interaction with ACE inhibitors and ARBs requires careful study design.
- Oral bioavailability is lower than injectable; optimal dosing unclear.
- Not FDA-approved for therapeutic use.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Angiotensin-(1-7) vs GHK-Cu (Oral) — Key differences
- Class: Angiotensin-(1-7) is classified as Cardiovascular · Anti-inflammatory, while GHK-Cu (Oral) is Systemic · Regeneration.
- Primary research focus: Angiotensin-(1-7) — pulmonary hypertension and fibrosis; GHK-Cu (Oral) — systemic tissue repair and regeneration.
- Tag: Cardiovascular · Anti-inflammatory vs Systemic · Anti-aging.